Is BHRT safe long-term?

BHRT may be safe long-term for appropriately selected patients, but it should not be treated as a “set it and forget it” therapy. Long-term safety depends on the specific hormone used, the route of delivery, the dose, the reason for treatment, your age, your personal risk factors, and how closely you are monitored. Bioidentical hormone replacement therapy uses hormones that match the structure of hormones naturally made by the body, such as estradiol, micronized progesterone, and testosterone. That does not make BHRT risk-free, but it does mean that modern, individualized hormone therapy should be evaluated differently than older, one-size-fits-all hormone regimens.

Key Points

• Long-term BHRT safety is individualized. The question is not simply how many years someone has used hormones. Safety depends on the hormone, route, dose, timing, health history, and whether the treatment is still providing meaningful benefit.
• Current research does not support one blanket cutoff age. Some patients may continue hormone therapy beyond the early menopause years when benefits still outweigh risks. Ongoing use should be reviewed regularly rather than stopped automatically because of age alone.
• Route matters, especially for estrogen. Oral estrogen and transdermal estradiol do not behave the same way in the body. Transdermal estradiol, such as patches, gels, or creams, is often preferred in a risk-aware practice because it largely bypasses first-pass liver metabolism.
• Dose matters over time. Long-term therapy should generally use the lowest effective dose that controls symptoms and supports the treatment goal. More hormone is not automatically better, and needs may change with age, weight, sleep, stress, medications, and health status.
• Progesterone and uterus status matter. If a woman has a uterus and uses systemic estrogen, progesterone or another appropriate progestogen is usually needed to protect the uterine lining. Progesterone may also be appropriate for some women who no longer have a uterus, but the reason is different and should be individualized.
• Monitoring is what makes long-term care responsible. BHRT should be reassessed over time through symptom review, side-effect checks, bleeding review, blood pressure, health screenings, medication updates, and labs when clinically appropriate. Long-term use should remain an active clinical decision.

Understanding Long-Term BHRT Safety

BHRT stands for bioidentical hormone replacement therapy. “Bioidentical” means the hormone has the same molecular structure as a hormone naturally made by the body. Common examples include estradiol, micronized progesterone, and testosterone.

Long-term safety is often misunderstood because many people still think of hormone therapy as one single risk category. In reality, oral conjugated estrogens, synthetic progestins, transdermal estradiol, micronized progesterone, vaginal estrogen, testosterone therapy, pellets, creams, injections, and compounded preparations all have different considerations.

Older hormone therapy concerns came largely from studies using specific regimens in specific populations, often not the same as the modern individualized approaches used in many BHRT practices today. Those studies still matter, but they should not be applied too broadly to every patient, every route, or every hormone molecule.

The more useful long-term safety question is: which hormone is being used, at what dose, by what route, for which patient, at what stage of life, with what personal risks, and with what monitoring plan?

Long-term BHRT may be reasonable for some patients, especially when symptoms return after stopping or when therapy supports quality of life, vaginal and urinary health, sleep, bone health, or other individualized goals. But long-term use should always be reviewed periodically to confirm that the benefits still outweigh the risks.

What Current Research Says About Longer-Term Use

Recent research continues to show that hormone therapy safety varies by type, route, and dose. A 2024 study looking at menopausal hormone therapy use beyond age 65 found that outcomes differed depending on estrogen type, administration route, and dose strength. In general, lower-dose, non-oral, and estradiol-based approaches appeared more favorable than higher-dose or oral approaches.

That does not mean everyone should stay on hormones indefinitely. It does mean that age alone is not the only factor. A healthy 66-year-old using a carefully monitored low-dose transdermal estradiol plan may have a different risk profile than someone using higher-dose oral therapy with multiple cardiovascular or clotting risk factors.

A 2024 BMJ study also highlighted that different hormone combinations and administration methods have different cardiovascular risk patterns. One important detail is that “progestin” and “progesterone” are not the same thing. Progestins are synthetic progesterone-like medications, while micronized progesterone is bioidentical to the progesterone the body naturally makes. In that study, oral estrogen-progestin therapy was associated with a higher risk of heart disease and venous thromboembolism, while findings varied across other formulations and routes. This does not mean every estrogen-plus-progesterone plan carries the same risk; it means the specific estrogen, the route, and whether the progestogen is a synthetic progestin or bioidentical progesterone all matter. That is why long-term BHRT safety should be discussed by exact regimen instead of saying all hormone therapy is either “safe” or “dangerous.”

For many women, the benefit-risk profile is often most favorable when hormone therapy starts closer to menopause, especially before age 60 or within about 10 years of the final menstrual period. Starting later does not always rule out treatment, but it usually requires a more cautious review of cardiovascular risk, clotting history, route, dose, and alternatives.

The key long-term principle is periodic reassessment. The safest plan at 52 may not be the same plan needed at 62 or 72. Hormone therapy should evolve with the patient.

Long-Term Estrogen Safety

Estrogen is often the center of the long-term safety conversation. It can be very effective for hot flashes, night sweats, sleep disruption, vaginal and urinary symptoms, and bone health in appropriate candidates. But the route and dose matter.

Oral estrogen is absorbed through the digestive tract and processed through the liver before reaching the rest of the body. This first-pass liver effect can influence clotting factors, triglycerides, inflammatory markers, and other cardiovascular-related pathways. For some patients, that matters more as they age or develop additional risk factors.

Transdermal estradiol, such as a patch, gel, or cream, enters through the skin and largely bypasses first-pass liver metabolism. Because of this, transdermal estradiol is often preferred in a risk-aware practice, especially for patients with clotting concerns, cardiovascular risk factors, migraine concerns, metabolic issues, or sensitivity to oral medication.

Vaginal estrogen is different from systemic estrogen. It is typically used for local symptoms such as vaginal dryness, painful sex, urinary urgency, or recurrent urinary discomfort. Because systemic absorption is generally low, vaginal estrogen is often considered separately from full-body hormone therapy, though personal history still matters.

Long-term estrogen therapy should be reviewed in the context of symptoms, bone health, cardiovascular risk, breast health, bleeding pattern, medication changes, and patient preference. The goal is not to use the highest dose possible; the goal is to use the safest effective plan for the reason therapy is being used.

Long-Term Progesterone And Progestogen Safety

Progesterone is especially important for women who have a uterus and use systemic estrogen. Estrogen can stimulate the uterine lining, also called the endometrium. Without adequate progesterone or another appropriate progestogen, the lining may overgrow and increase the risk of abnormal bleeding or endometrial cancer.

Micronized progesterone is bioidentical to the progesterone made by the body. It is not the same as synthetic progestins, which are different molecules and may have different effects on breast tissue, mood, sleep, clotting, and cardiovascular markers.

For long-term care, the type of progestogen matters. A patient using estradiol with micronized progesterone is not necessarily in the same risk category as someone using a different estrogen with a synthetic progestin. This is why hormone therapy should be discussed by specific regimen, not just by the broad label “HRT.”

Progesterone may also be appropriate for some women who no longer have a uterus, especially when it supports sleep, mood, or overall hormone balance, but the reason for prescribing it is different than uterine protection and should be individualized.

Long-term progesterone monitoring should include sleep response, mood, grogginess, dizziness, bloating, breast tenderness, and bleeding patterns when relevant. If bleeding occurs after menopause or becomes heavy, persistent, or unusual, it should be evaluated rather than assumed to be a normal side effect.

Long-Term Testosterone Safety

Testosterone safety should be discussed separately because the concerns and monitoring needs are different. In men with clinically meaningful low testosterone, recent research has been more reassuring than older assumptions about cardiovascular and prostate risk when therapy is prescribed and monitored appropriately.

Long-term testosterone therapy still requires careful follow-up. One of the most important markers is hematocrit, which is the percentage of red blood cells in the blood. Testosterone can raise red blood cell production, and if hematocrit becomes too high, the treatment plan may need to be adjusted.

For men, monitoring may also include testosterone levels, symptoms, blood pressure, sleep apnea symptoms, mood, acne, swelling, fertility goals, prostate-related evaluation when appropriate, and cardiovascular risk factors. Testosterone should not be used simply for general anti-aging or performance enhancement.

For women, testosterone may be considered selectively, often for low sexual desire or broader hormone optimization in carefully selected cases. The dose for women must be much lower than male dosing. Too much testosterone can cause acne, oily skin, unwanted facial hair growth, scalp hair thinning, irritability, or voice changes.

Long-term testosterone safety depends on staying in an appropriate range, watching symptoms closely, and avoiding dose escalation that creates side effects without added benefit.

Who It’s For And Who Should Be Cautious

Long-term BHRT may be appropriate for women whose symptoms return when therapy is stopped, women with persistent hot flashes or night sweats, women with genitourinary symptoms of menopause, women using hormone therapy as part of a bone-health strategy, or women who continue to have clear quality-of-life benefits after individualized risk review.

For men, long-term testosterone therapy may be appropriate when symptoms and properly interpreted labs confirm hypogonadism, and when ongoing monitoring shows that treatment remains safe and beneficial. Therapy should be reassessed if risks change or benefits fade.

People who need extra caution include those with a history of hormone-sensitive cancer, unexplained vaginal bleeding, blood clots, stroke, significant liver disease, uncontrolled high blood pressure, active cardiovascular disease, untreated sleep apnea, very high hematocrit, or complex medication histories. These situations do not always mean hormone therapy is impossible, but they require a more careful plan and sometimes specialist input.

Age is part of the discussion, but it should not be the only deciding factor. Route, dose, cardiovascular health, clotting history, cancer history, bone health, symptom severity, and patient preference all matter. Some patients may continue therapy safely, while others may do better with dose reduction, route changes, local therapy, non-hormonal options, or discontinuation.

Long-term BHRT should be a shared decision. The provider and patient should periodically ask whether therapy is still helping, whether risks have changed, and whether the current route and dose still make sense.

Risks, Side Effects, and Monitoring

BHRT can cause side effects, even when used carefully and even when the hormones are bioidentical. Common side effects may include breast tenderness, bloating, headaches, nausea, spotting or irregular bleeding, skin irritation from patches or creams, acne, fluid retention, mood changes, sleep changes, or changes in libido. These are often dose- or route-related and may improve with adjustment.

More serious risks depend on the hormone and the patient. Estrogen therapy may affect clotting risk, stroke risk, gallbladder disease, breast symptoms, and uterine lining safety depending on route, dose, timing, duration, and whether progesterone is needed. Testosterone therapy may raise hematocrit, worsen acne or hair thinning, affect mood, contribute to fluid retention, or worsen untreated sleep apnea.

Long-term monitoring should include symptom response, side effects, blood pressure, weight and metabolic changes, bleeding patterns, breast or prostate considerations when relevant, medication interactions, and appropriate labs. For women using systemic estrogen with a uterus, uterine protection must remain part of the plan. For men using testosterone, hematocrit monitoring is especially important.

Compounded BHRT also requires thoughtful oversight. Compounded prescriptions can be useful when custom dosing, inactive-ingredient flexibility, or a specific delivery form is clinically needed. The key distinction is that the components may be FDA-approved or pharmaceutically recognized, but the final compounded prescription is not reviewed by the FDA in the same way as a commercially manufactured drug.

Long-term safety improves when treatment is individualized, started at a thoughtful dose, adjusted based on response, and revisited over time. Hormone needs can change with age, weight changes, surgery, medications, stress, sleep, thyroid function, cardiovascular health, and evolving personal risk factors.

Safety

Seek urgent medical care right away for chest pain, shortness of breath, one-sided weakness or numbness, sudden severe headache, vision changes, fainting, calf pain or swelling, coughing up blood, or heavy vaginal bleeding. These symptoms can signal rare but serious problems such as a blood clot, stroke, pulmonary embolism, or significant bleeding.

Call your provider for non-urgent but important concerns such as persistent breast tenderness, mood changes, acne, scalp hair shedding, patch irritation, unexpected spotting, postmenopausal bleeding, worsening sleep, swelling, or symptoms that worsen after a dose change. Do not adjust your dose on your own.

If you take medications for blood pressure, blood thinning, thyroid disease, diabetes, seizures, mood, fertility, or cardiovascular conditions, hormone therapy decisions should be coordinated with your prescribing clinician. If you are under the care of an oncologist, cardiologist, gynecologist, urologist, endocrinologist, or another specialist, your BHRT provider should coordinate when needed.

Sources and Citations

• Use of Menopausal Hormone Therapy Beyond Age 65 Years and Its Effects on Women’s Health Outcomes by Types, Routes, and Doses — Menopause
• Contemporary Menopausal Hormone Therapy and Risk of Cardiovascular Disease — BMJ
• Cardiovascular Risk Associated with Menopause and Menopause Hormone Therapy — PMC
• The 2025 Menopausal Hormone Therapy Guidelines — PMC
• Prostate Risk and Monitoring During Testosterone Replacement Therapy — JAMA Network Open